Hormone therapyFDA-approvedFirst-line

Relugolix

How it works

Blocks the production of androgens (male hormones) that fuel prostate cancer growth, slowing tumor growth.

Cancer types

Prostate Cancer— All patients

Efficacy

Studies show that relugolix can improve metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer.

Side effects

Mild

Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.

Evidence from research

StudyCancer typeStageEfficacy
Testing Relugolix with Radiation Therapy for Advanced Prostate CancerProstate Cancerphase-2—Source →
Prostate Cancer Study: Relugolix and SBRT TreatmentProstate Cancerphase-2—Source →
Study of Relugolix in Patients with Prostate CancerProstate Cancerpreclinical—Source →
New Oral Treatment for Advanced Prostate Cancer Shows PromiseProstate Cancerphase-3Relugolix was associated with a 54% reduction in the risk of major adverse cardiovascular events.Source →
Potential New Side Effects of Cancer Treatment RelugolixProstate Cancerobservational—Source →
New Study Compares Cancer Treatment Efficacy in Men with Heart ConditionsProstate Cancerphase-3A 54% lower incidence of major adverse cardiac events was reported in men treated with relugolix vs leuprolide.Source →
Concerns Raised Over Relugolix Approval for Prostate CancerProstate Cancerphase-3—Source →
Relugolix vs Leuprolide for Advanced Prostate CancerProstate Cancerphase-397% of men taking relugolix achieved sustained castration through 48 weeks, compared to 89% of men receiving leuprolide.Source →
Advances in Treating Advanced Prostate CancerProstate Cancerreview—Source →
Managing Metastatic Prostate Cancer: New Treatment OptionsProstate Cancerreview—Source →

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.